Other Viruses Citation List: December 5 - December 18, 2014

Hepatitis C Virus

1. Potent Bisimidazole-based HCV NS5A Inhibitors Bearing Annulated Tricyclic Motifs. Zhong, M., E. Peng, N. Huang, Q. Huang, A. Huq, M. Lau, R. Colonno, and L. Li. Bioorganic & Medicinal Chemistry Letters, 2014. 24(24): p. 5738-5742. PMID[25453811].

[PubMed]. OV_1205-121814.

2. Discovery of Functionalized Bisimidazoles Bearing Cyclic Aliphatic-phenyl Motifs as HCV NS5A Inhibitors. Zhong, M., E. Peng, N. Huang, Q. Huang, A. Huq, M. Lau, R. Colonno, and L. Li. Bioorganic & Medicinal Chemistry Letters, 2014. 24(24): p. 5731-5737. PMID[25453810].

[PubMed]. OV_1205-121814.

3. Interferon-inducible Cholesterol-25-hydroxylase Inhibits Hepatitis C Virus Replication via Distinct Mechanisms. Chen, Y., S. Wang, Z. Yi, H. Tian, R. Aliyari, Y. Li, G. Chen, P. Liu, J. Zhong, X. Chen, P. Du, L. Su, F.X. Qin, H. Deng, and G. Cheng. Scientific Reports, 2014. 4: p. 7242. PMID[25467815].

[PubMed]. OV_1205-121814.

Citations from the ISI Web of Knowledge Listings for O.V.

4. HCV Nucleoside Inhibitors Can Exhibit Genotype Specific Differences in Activity. Anton, E.D., K. Strommen, W. Huang, A.A. Rivera, C.J. Petropoulos, F. Amblard, R.F. Schinazi, and J.D. Reeves. Hepatology, 2014. 60: p. 1169A-1170A. ISI[000344483805066].

[WOS]. OV_1205-121814.

5. MK-8408, a Potent and Selective NS5A Inhibitor with a High Genetic Barrier to Resistance and Activity against HCV Genotypes 1-6. Asante-Appiah, E., R. Liu, S. Curry, P. McMonagle, S. Agrawal, D. Carr, L. Rokosz, F. Lahser, K. Bystol, R. Chase, S. Black, E.B. Ferrari, P. Ingravallo, S.Y. Chen, L. Tong, W.S. Yu, and J. Kozlowski. Hepatology, 2014. 60: p. 1163A-1164A. ISI[000344483805054].

[WOS]. OV_1205-121814.

6. IDX21459, a Uridine Nucleotide Prodrug, Shows a Favorable Preclinical Profile as a Direct-acting Antiviral Agent (DAA) against HCV. Chapron, C.D., K.S. Gupta, M. La Colla, B. Hernandez-Santiago, M. Seifer, H. Rashidzadeh, I. Serra, S.Q. Luo, X.R. Pan-Zhou, C. Brynczka, B. Heinrich, J.S. Lim, F.R. Alexandre, and R. Rush. Hepatology, 2014. 60: p. 1172A-1173A. ISI[000344483805072].

[WOS]. OV_1205-121814.

7. The Antiviral Profile of TG-2349, a Novel HCV Protease Inhibitor with Pan-Genotypic Activity. Chen, C.M., Y.F. Chen, C.C. Lin, C.H.R. King, and M.C. Hsu. Hepatology, 2014. 60: p. 1172A-1172A. ISI[000344483805071].

[WOS]. OV_1205-121814.

8. Facile Synthesis of Mollugin by Kinetic Control and anti-HCV (Hepatitis C Virus) Activity of Its Analogues. Choi, D.H., N.R. Lee, C.G. Kim, J.W. Kim, S.W. Lee, and J.G. Jun. Bulletin of the Korean Chemical Society, 2014. 35(11): p. 3232-3238. ISI[000344583300017].

[WOS]. OV_1205-121814.

9. CPI-431-32, a Novel Cyclophilin A Inhibitor, Simultaneously Blocks Replication of HCV and HIV-1 Viruses in a Novel in Vitro Co-infection Model. Gallay, P., M. Bobardt, D. Trepanier, D. Ure, C. Ordonez, and R.T. Foster. Hepatology, 2014. 60: p. 1128A-1128A. ISI[000344483804489].

[WOS]. OV_1205-121814.

10. (-)-Epigallocatechin-3-gallate Inhibits Entry of Hepatitis B Virus into Hepatocytes. Huang, H.C., M.H. Tao, T.M. Hung, J.C. Chen, Z.J. Lin, and C. Huang. Antiviral Research, 2014. 111: p. 100-111. ISI[000345185100015].

[WOS]. OV_1205-121814.

11. Evaluation of TG-2349, a Novel HCV Protease Inhibitor with Pan-genotypic Activity, in Replicon-mouse Models with Luciferase Reporter. Huang, Y.H., C.M. Chen, H.M. Hsu, C.C. Lin, C.H.R. King, and M.C. Hsu. Hepatology, 2014. 60: p. 1171A-1171A. ISI[000344483805069].

[WOS]. OV_1205-121814.

12. The Combination of MK-5172, an NS3 Inhibitor, and MK-8408, an NS5A Inhibitor, Presents a High Genetic Barrier to Resistance in HCV Genotypes. Lahser, F., K. Bystol, S. Curry, P. McMonagle, R. Liu, E. Xia, R. Chase, S. Black, E.B. Ferrari, L. Tong, W.S. Yu, J. Kozlowski, and E. Asante-Appiah. Hepatology, 2014. 60: p. 1168A-1168A. ISI[000344483805063].

[WOS]. OV_1205-121814.

13. Vinylated Linear P2 Pyrimidinyloxyphenylglycine Based Inhibitors of the HCV NS3/4A Protease and Corresponding Macrocycles. Lampa, A., H. Alogheli, A.E. Ehrenberg, E. Akerblom, R. Svensson, P. Artursson, U.H. Danielson, A. Karlen, and A. Sandstrom. Bioorganic & Medicinal Chemistry, 2014. 22(23): p. 6595-6615. ISI[000345287300007].

[WOS]. OV_1205-121814.

14. A Next Generation HCV DAA Combination: Potent, Pangenotypic Inhibitors ABT-493 and ABT-530 with High Barriers to Resistance. Ng, T., T. Pilot-Matias, L.J. Lu, T. Reisch, T. Dekhtyar, P. Krishnan, J. Beyer, R. Tripathi, R.B. Pithawalla, A. Asatryan, A.L. Campbell, J. Kort, and C. Collins. Hepatology, 2014. 60: p. 1142A-1142A. ISI[000344483805021].

[WOS]. OV_1205-121814.

15. Downregulation of Inducible Nitric Oxide Synthase (iNOS) Expression is implicated in the Antiviral Activity of Acetylsalicylic acid in HCV-expressing Cells. Rios-Ibarra, C.P., S. Lozano-Sepulveda, L. Munoz-Espinosa, A.R. Rincon-Sanchez, C. Cordova-Fletes, and A.M.G. Rivas-Estilla. Archives of Virology, 2014. 159(12): p. 3321-3328. ISI[000344804200014].

[WOS]. OV_1205-121814.

16. Quercetin Inhibits Both Replication and Assembly of Hepatitis C Virus by Blocking the Viral NS3 and the Host Diacylglycerol Acyltransferase Type 1. Rojas, A., S. Clement, M. Lemasson, J.A. Del Campo, M. Garcia-Valdecasas, A. Gil-Gomez, I. Ranchal, J. Bautista, A.R. Rosenberg, F. Negro, and M. Romero-Gomez. Hepatology, 2014. 60: p. 1078A-1078A. ISI[000344483804391].

[WOS]. OV_1205-121814.

17. Mipomersen, an FDA-approved Anti-sense Inhibitor of apoB100, has anti-HCV Effect in-Vitro. Schaefer, E.A., J. Meixiong, D.L. Motola, D. Fusco, C. Brisac, S. Salloum, J. Luther, W.Y. Lin, M.P. McGowan, L.F. Peng, and R.T. Chung. Hepatology, 2014. 60: p. 1050A-1050A. ISI[000344483804331].

[WOS]. OV_1205-121814.

18. A 4-N-Hydroxycytidine ribonucleoside phosphoramidate delivers Intracellularly Three Distinct Active 5'-Triphosphate Nucleosides That are Potent Inhibitors of HCV Polymerase. Schinazi, R.F., F. Amblard, S.J. Tao, M. Ehteshami, S. Amiralaei, H. Li, J. Shelton, T. Whitaker, T.R. McBrayer, and S.J. Coats. Hepatology, 2014. 60: p. 1162A-1162A. ISI[000344483805050].

[WOS]. OV_1205-121814.

19. Synthesis of 3',4'-Difluoro-3'-deoxyribonucleosides and Its Evaluation of the Biological Activities: Discovery of a Novel Type of anti-HCV Agent 3',4'-Difluorocordycepin. Shimada, H., K. Haraguchi, K. Hotta, T. Miyaike, Y. Kitagawa, H. Tanaka, R. Kaneda, H. Abe, S. Shuto, K. Mori, Y. Ueda, N. Kato, R. Snoeck, G. Andrei, and J. Balzarini. Bioorganic & Medicinal Chemistry, 2014. 22(21): p. 6174-6182. ISI[000344471800046].

[WOS]. OV_1205-121814.

20. New Lignans from the Roots of Didymocarpus hedyotideus and Their Antiviral Effect on Hepatitis B Virus. Tang, W.J., X. Chen, and L.H. Yang. Latin American Journal of Pharmacy, 2014. 33(6): p. 948-953. ISI[000344931600011].

[WOS]. OV_1205-121814.

21. ACH-3422, A Novel HCV NS5B RNA Polymerase Nucleotide Inhibitor, Demonstrates Improved Potency over Sofosbuvir against HCV Genotype-3 Replicons in Vitro. Zhao, Y.S., S. Podos, J.L. Fabrycki, D. Patel, W.G. Yang, G.W. Yang, J. Wiles, A. Phadke, and M.J. Huang. Hepatology, 2014. 60: p. 1163A-1163A. ISI[000344483805053].

[WOS]. OV_1205-121814.